Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2 +/− rat model
Abstract Impaired function of the retinal neurovascular unit (NVU) is an early event in diabetic retinopathy (DR). It has been previously shown that topical delivery of the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin can protect against diabetes-mediated dysfunction of the retinal NVU in th...
Saved in:
| Main Authors: | Hugo Ramos, Josy Augustine, Burak M. Karan, Cristina Hernández, Alan W. Stitt, Tim M. Curtis, Rafael Simó |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Neuroinflammation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12974-024-03283-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ocular and Plasma Pharmacokinetics of Sitagliptin Eye Drops: Preclinical Data
by: Cristina Hernández, et al.
Published: (2024-11-01) -
Sitagliptin: a potential drug for the treatment of COVID-19?
by: Bardaweel Sanaa K., et al.
Published: (2021-06-01) -
A biomechanical study of the role of sitagliptin on the bone characteristics of diabetic rats
by: Stavros K Kourkoulis, et al.
Published: (2020-01-01) -
The Impact of Sitagliptin on Sodium Valproate-Induced Autism in a Mouse Model
by: Ahmed Sudan Abbas, et al.
Published: (2024-09-01) -
Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
by: Soumitra Ray, et al.
Published: (2024-04-01)